Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics
This article was originally published in PharmAsia News
Executive Summary
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies
You may also be interested in...
BGI CEO Wang Jun On Big Data, Drug Development And Fundamental Innovation: An Interview With PharmAsia News (Part 1 of 2)
Named “one of the ten people who mattered” in 2012 by the journal Nature, the BGI-Shenzhen co-founder talks about how big data will change the course of R&D, from drug development to agriculture to a new carbon world.
Collaboration Key To Chinese Innovation And Global Ambitions – China Healthcare Investment Conference
BGI CEO Jun Wang and Simcere Founder Jisheng Ren share views on collaboration and talent retention in China.
Collaboration Key To Chinese Innovation And Global Ambitions – China Healthcare Investment Conference
BGI CEO Jun Wang and Simcere Founder Jisheng Ren share views on collaboration and talent retention in China.